Inhibitory effects of Δ8-tetrahydrocannabinol on major hepatic cytochrome P450 enzymes and implications for drug disposition
Open Access
- 16 July 2025
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (9) , 100122
Abstract
No abstract availableKeywords
Funding Information
- State of Washington (171)
- National Cancer Institute (7R01CA269223)
- National Institutes of Health
This publication has 57 references indexed in Scilit:
- A within-subject cross-over trial comparing the acute effects of oral delta-8-tetrahydrocannabinol and delta-9-tetrahydrocannabinol in healthy adultsDrug and Alcohol Dependence, 2025
- Quantitative Contributions of Hepatic and Renal Organic Cation Transporters to the Clinical Pharmacokinetic Cimetidine–Metformin InteractionClinical Pharmacology & Therapeutics, 2025
- In vitro assessment of inhibitory effects of kinase inhibitors on CYP2C9, 3A and 1A2: Prediction of drug-drug interaction risk with warfarin and direct oral anticoagulantsEuropean Journal of Pharmaceutical Sciences, 2024
- Adolescent Δ8-THC and Marijuana Use in the USJAMA, 2024
- The Public Health Challenge of Δ8-THC and Derived Psychoactive Cannabis ProductsJAMA, 2024
- Marijuana and endoscopy: the effects of marijuana on sedationGastrointestinal Endoscopy, 2024
- Public interest in ∆8-Tetrahydrocannabinol (delta-8-THC) increased in US states that restricted ∆9-Tetrahydrocannabinol (delta-9-THC) useInternational Journal of Drug Policy, 2021
- A survey of cannabinoids and toxic elements in hemp-derived products from the United States marketplaceJournal of Food Composition and Analysis, 2021
- Stereoselective Metabolism of Bupropion by Cytochrome P4502B6 (CYP2B6) and Human Liver MicrosomesPharmaceutical Research, 2008
- Physicochemical Properties, Solubility, and Protein Binding of Δ9 -TetrahydrocannabinolJournal of Pharmaceutical Sciences, 1974